Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690

NCT04046250 | Completed Phase 2 Results FDA Drug

• 1 other identifier: CLP-2690-0003
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 3

Brief Summary

Patients will receive methotrexate at a dose of 45 mg/m2 administered weekly for 4 consecutive weeks as an iv infusion along with a nutritional supplement administered two hours before the methotrexate. One hour before the methotrexate treatment the patients will be administered the first infusion of the day of either TK112690 or placebo depending on randomization. Five hours after the methotrexate treatment the patients will be administered the second treatment of either TK112690 or placebo depending on randomization. The TK112690 dose will be 45 mg/kg.

Conditions

Mucositis

Keywords

Mucositis; Methotrexate; Uridine Phosphorylase Inhibitor; Head and Neck Cancer

Outcome Measures

Primary Outcomes (1)

• Mucositis

  Mucositis Evaluation Using Established Scoring Systems: NCI/CTCAE at 4 WKs (Primary) and WHO at 4 WKs (Primary). NCI/CTCAE=National Cancer Institute/Common Terminology Criteria for Adverse Events and WHO=World Health Organization NCI Grades- 0= No mucositis, 1=Mild mucositis (Painless ulcers, erythema, or mild soreness in the absence of lesions), 2=Moderate mucositis (Painful erythema, edema, or ulcers but eating or swallowing possible), 3= Severe mucositis (Painful erythema, edema, or ulcers requiring IV hydration), 4=Life threatening, 5=Death WHO Grades- 0=No mucositis, 1= Mild (Oral soreness, erythema), 2=Moderate (Oral erythema, ulcers, solid diet tolerated), 3=Severe (Oral ulcers, liquid diet only), 4=Life-threatening (Oral alimentation impossible). For both the scales above, a higher score implies greater mucositis. Scale specific mean values for patients in each group (placebo or treated) are calculated and compared by Student's t-test.

  up to 4 Weeks

Secondary Outcomes (1)

• Incidence Adverse Events That Are Related to Treatment

  Measured Weekly Over 4 Weeks of Study

Study Arms (2)

TK112690

EXPERIMENTAL

TK112690 treatment

Drug: TK-112690

Placebo

PLACEBO COMPARATOR

TK112690 formulation

Drug: Placebo TK-112690

Interventions

TK-112690 DRUG

TK112690 treatment pre-methotrexate treatment

Also known as: Treatment

TK112690

Placebo TK-112690 DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects over 18 years old with a histologically or cytological confirmed diagnosis of locally residual, recurrent or metastatic SCCHN.
• Subject must have failed at least one courses of non-MTX chemotherapy, or one course of non-MTX chemotherapy and chemo radiation for treating their SCCHN.
• No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks prior to screening.
• No other concurrent, active, invasive malignancies.
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• Must have a life expectancy of at least 6 months.
• History of brain metastases allowed if disease has stabilized or improved after radiation and/or craniotomy.
• No active angina or uncontrolled arrhythmia.
• No detectable infection including hepatitis B/C and HIV.
• Not pregnant or nursing. Women of childbearing potential must have a negative urine pregnancy test at screening and on the day before dosing and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or post-menopausal for ≥ 1 year, must be specified in the patient's medical history file and CRF.
• Must have adequate organ and immune function as indicated by the following laboratory values:
• Parameter Laboratory Values Serum creatinine ≤1.5 x ULN Est. creatinine clearance ≥45 mL/min Total bilirubin ≤2.0 mg/dL (≤34.2 μmol/L) AST \& ALT ≤3 x ULN Absolute granulocytes ≥1.5 x 109 cells/L Platelets ≥100,000/µL
• ● Be able to read and understand, and provide a signature or thumb impression on the Informed Consent Form (ICF) before entering the study.

You may not qualify if:

• Subject has not failed at least one courses of non-MTX chemotherapy or one course of non-MTX chemotherapy and chemo radiation for treating their SCCHN.
• Uncontrolled active infection.
• Current mucositis (\>Grade 1).
• Pregnant or nursing mother.
• Prior history of a cerebrovascular accident or hemorrhage.
• Congestive heart failure, as defined by New York Heart Association class III or IV.
• Uncontrolled hypertension.
• Active psychiatric/mental illness making informed consent or useful clinical follow-up unlikely.
• Subjects who have previously been enrolled into this study and subsequently withdrew.
• Subject receiving other investigational agent(s).
• Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids).
• Any significant systemic illness, unstable or severe medical condition(s) that could put the subject at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures such as intercurrent infection and/or autoimmune disease, ie, any condition that compromises the immune system.
• Known or suspected intolerance or hypersensitivity to the study materials (TK-112690 and/or excipients or closely related compounds).
• Subjects, who have received, or plan to receive, radiation or chemotherapy within 4 weeks of screening.
• Subjects that have a history of poor compliance in clinical research studies.

Sponsors & Collaborators

• Tosk, Inc.: lead
• Crystal Life Sciences: collaborator

Study Sites (3)

Bangalore Cancer

Bangalore, Karnataka, 560091, India

Location

Karnatak Cancer Therapy and Research Institute

Navanagar, Karnataka, 580025, India

Location

Netaji Subhash Chandra Bose Cancer Hospital

Kolkata, West Bengal, 700094, India

Location

MeSH Terms

Conditions

Mucositis; Head and Neck Neoplasms

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Mouth Diseases; Stomatognathic Diseases; Neoplasms by Site; Neoplasms

Results Point of Contact

• Title: Emile Youssef, MD, PhD
• Organization: Tosk, Inc.

eyoussef@tosk.com

312.244.0068

Study Officials

• Emile Youssef, MD, PhD

  Tosk, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: The study will be partially blinded. The patient and investigator will be blinded as to whether TK112690 or placebo is administered. The clinical research organization, sponsor, and site pharmacist will know whether the patient was administered active drug or placebo.
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: A total of 22 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated.

Study Record Dates

• First Submitted: August 1, 2019
• First Posted: August 6, 2019
• Study Start: May 15, 2019
• Primary Completion: October 10, 2019
• Study Completion: March 31, 2020
• Last Updated: August 25, 2023
• Results First Posted: June 3, 2021

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

IN (3)